Prokineticin‐2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients
Background Elevated levels of prokineticin‐2 (PK2), regarded as a protein involved in modulating immune/inflammatory responses, have been detected in the substantia nigra, serum, and olfactory neurons of Parkinson's disease (PD) patients. Of note, emerging evidence suggests that gut alterations...
Saved in:
Published in | Movement disorders Vol. 39; no. 11; pp. 2091 - 2097 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.11.2024
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Elevated levels of prokineticin‐2 (PK2), regarded as a protein involved in modulating immune/inflammatory responses, have been detected in the substantia nigra, serum, and olfactory neurons of Parkinson's disease (PD) patients. Of note, emerging evidence suggests that gut alterations, including dysbiosis and enteric inflammation, play a role in PD via the gut‐brain axis.
Objectives
Our goal was to investigate the expression of PK2 in colonic biopsies of PD patients.
Methods
Mucosal biopsies from the descending colon were obtained in 11 PD patients and five asymptomatic subjects. Biopsy samples were processed for PK2 immunofluorescence and western blot.
Results
We revealed an increased PK2 expression in colonic mucosa from PD patients in the early stages compared to controls. In addition, we found that PK2 was expressed by activated enteric glial cells and macrophages.
Conclusions
PK2 is highly expressed within neurogenic/inflammatory cells of colonic mucosa from early PD patients, suggesting a potential role of PK2 in gut inflammation, especially in the early stages of PD. © 2024 International Parkinson and Movement Disorder Society. |
---|---|
Bibliography: | The authors report no competing interests. No financial disclosures to declare. This research received no specific grant from any funding agency in the public, commercial, or not‐for‐profit sectors. Relevant conflicts of interest/financial disclosures Gabriele Bellini and Francesco Rettura equally contributed to this work and should be considered co‐first authors. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0885-3185 1531-8257 1531-8257 |
DOI: | 10.1002/mds.29937 |